Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2025.199 | A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Squamous Solid Tumors | Prof. MA Brigette Buig Yue |
| 2020.054 | A phase I/Ib, open-label, multi-center, study of KAZ954 as a single agent and in combination with Spartalizumab, NZV930 and NIR178 in patients with advanced solid tumors |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2019.153 | A Phase I/Ib, open-label, multi-center study of NZV930 as a single agent and in combination with PDR001 and/or NIR178 in patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2017.540 | A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2010.251 | Uncontrolled, open-label, non-randomized, phase 1 study to investigate the pharmacokinetics, safety, tolerability, and efficacy of BAY 73-4506 in Chinese patients with advanced, refractory solid tumors | Associate Professor Ma Brigette Buig-Yue |
| 2010.473 | An East Asian phase I, multicenter, open-label, dose-escalation study of oral LDE225 in patients with advanced solid tumors | Associate Prof. Ma Buig Yue Brigette |
| 2010.466 | SAVOR Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus A Multicenter, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes | Professor Ma Ching Wan Ronald |
| 2012.052 | An evaluation on the effectiveness, acceptability and pricing of annual complication assessment for people with diabetes mellitus in the Hong Kong Community | Prof Ma Ching-wan, Ronald |
| 2017.282 | Mindfulness-based cognitive therapy for community-dwelling adults with anxiety symptoms: An exploration of efficacy and cognitive mechanism |
Miss MA Duan Yang 馬端陽 |
| 2012.321 | An opinion Survey among frail elderly patients and their carers regarding their opinion about self-financed community care services | Dr MA HON MING |
| 2023.153 | Mitochondrial disease related mortality - evaluation of a large international cohort | Dr. MA Kam Hung |
| 2013.407 | Pharmacokinetic study of once-daily formulation of Tacrolimus (Advagraf_) in Chinese kidney transplant patients | Dr Ma King Wing, Terry |
| 2022.043 | Effects of a structured Tai Chi program on improving physical activity level, exercise self-efficacy, and health outcomes among pregnant women: A randomised controlled trial |
Ms. MA Nan 马楠 |
| 2015.241 | A Transdiagnostic Anger Management Program for Adult Psychiatric Inpatient |
Ms. MA Olivia 馬婉婷 |
| 2015.458 | The effect of imagery and rumination on depression: a mediation and intervention study |
Ms. MA Olivia 馬婉婷 |
| 2015.473 | Identification of genetic loci for birthweight and cardiometabolic traits in childhood |
Prof. MA Ronald 馬青雲 |
| 2015.040 | Progression of glucose intolerance, cardiometabolic risk factors and subclinical atherosclerosis in Chinese women with Polycystic Ovary Syndrome | Prof. MA Ronald |
| 2016.328 | Epigenetic markers of type 2 diabetes and diabetic complications |
Prof. MA Ronald 馬青雲 |
| 2016.103 | Unraveling the link between maternal hyperglycaemia and childhood obesity: Genome-wide methylation analysis in a prospective cohort of untreated gestational diabetes |
Prof. MA Ronald 馬青雲 |
| 2015.316 | Maternal exposure to Perfluorooctane sulfonate (PFOS) and the risk of childhood obesity and metabolic abnormalities in the offspring- analysis of a longitudinal birth cohort |
Prof. MA Ronald 馬青雲 |
| 2013.432 | Identification of epigenetic markers in offspring exposed to maternal hyperglycaemia | Prof. MA Ronald |
| 2022.475 | Translating multi-omic discoveries to transform diabetes care and reduce diabetic complications Substudy 1: A randomized controlled trial to evaluate the clinical utility of communicating polygenic risk scores in diabetes | Prof. MA Ronald |
| 2013.251 | An integrated trans-omics approach to diabetic cardio-renal complications: from novel discoveries to personalized medicine - Substudy 1: Transcriptome analysis of diabetic kidney disease | Prof. MA Ronald |
| 2008.518 | Progression of cardio-metabolic risk factors in Chinese women with Polycystic Ovary Syndrome | Prof Ma Ronald |
| 2013.187 | An integrated trans-omics approach to diabetic cardio-renal complications: from novel discoveries to personalized medicine | Prof. MA Ronald |
| 2013.304 | An integrated trans-omics approach to diabetic cardio-renal complications: from novel discoveries to personalized medicine Substudy 2: The Hong Kong Diabetes Biobank | Prof. MA Ronald |
| 2011.302 | Identificatin and large-scale replication of genetic predictors of diabetic kidney disease and diabetic retinopathy in the Chinese population | Prof Ma Ronald |
| 2011.354 | Identification of epigenetic markers associated with maternal diabetes and obesity | Prof. MA Ronald |
| 2008.519 | The role of neurohormonal dysregulation in the transgenerational effects of maternal diabetes | Prof Ma Ronald |
| 2013.042 | Identification of clinical and genetic predictors of hyperglycaemia and impaired beta-cell function in Chinese children- an analysis using mother-offspring pairs | Prof. MA Ronald |
| 2011.047 | Identification of genetic variants assocaited with atrial fibrillation and its effect in subjects with diabetes | Prof Ma Ronald |
| 2013.447 | Developing a Metagenomic Next-Generation Sequencing Software Platform for Discovering Biomarkers with Application to Obesity and Type 2 Diabetes | Prof. MA Ronald |
| 2011.118 | Genetic determinants of obesity and cardiometabolic traits in Chinese adolescents | Professor Ma Ronald |
| 2018.357 | Comprehensive evaluation and mechanism investigation of the PAX4 gene R192H variant on diabetes, diabetes-related traits and diabetic complications |
Prof. MA Ronald 馬青雲 |
| 2018.458 | Translating multi-omic discoveries to transform diabetes care and reduce diabetic complications |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2019.138 | Establishing the basis for Precision Medicine for Hyperglycaemia in Pregnancy-the Stratification of Hyperglycaemia in Pregnancy (SHIP) Study |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2020.120 | Type 2 Diabetes Organopathy by Magnetic Resonance Imaging (T2DOM) |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2020.287 | Effect and safety of semaglutide 2.4 mg once-weekly on weight management in subjects with overweight or obesity |
Dr. MA Ronald Ching Wan 馬青雲 |
| 2019.232 | Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL) |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2019.152 | Archival of human biological samples of Investigator-initiated studies in CU-Med Biobank | Prof. MA Ronald Ching Wan |
| 2019.315 | A multicenter, multinational, prospective, interventional, single-arm, Phase IV study evaluating the clinical efficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled on basal insulin |
Prof. MA Ronald Ching Wan 馬青雲教授 |
| 2018.476 | The Fenofibrate And Microvascular Events in Type 1 diabetes Eye. A randomised trial to evaluate the efficacy on retinopathy and safety of fenofibrate in adults with type 1 diabetes; A multicentre double-blind placebo-controlled study in Australia and Internationally |
Dr. MA Ronald Ching Wan 馬青雲 |
| 2023.118 | Identifying genetic determinants of drug response in Chinese patients with type 2 diabetes for precision therapeutics |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2022.207 | The impact of early-life exposure to metabolic abnormalities on pubertal development - from epidemiological analyses to mechanisms |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2022.141 | Using data to transform diabetes care and patient lives |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2021.559 | The use of NT-proBNP for stratifying risk of cardio-renal complications in Chinese patients with Type 2 diabetes |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2021.441 | A non-blinded retrospective biomarker add-on study to FIGARO-DKD for Bioprofiling the pharMacodynamic response to finerenone in FIGARO-DKD subjects (FIGARO-BM) |
Dr. MA Ronald Ching Wan 馬青雲 |
| 2023.527 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2023.608 | Hong Kong Precision Medicine in Diabetes Initiative | Prof. MA Ronald Ching Wan |
| 2023.146 | Improving Diabetes Care for young patients |
Prof. MA Ronald Ching Wan 馬青雲 |
Page 165 of 262.